SPECIAL REPORT: Understanding Treatment Dynamics and Needs in Juvenile Idiopathic Arthritis
Published By: Decision Resources
June 2009
R55-649
PDF E-mail From Publisher $4,500.00
Global Site License Fulfilled by Publisher $9,000.00
Description
Introduction
Although interviewed thought leaders acknowledge that available biological therapies have greatly
improved treatment of juvenile idiopathic arthritis (JIA)—the most common rheumatic disease
in children—they do not hesitate to point out unmet needs and remaining drug development
opportunities in this field. When current treatments fail, severe disability and even death can result.
The heterogeneous nature of JIA leaves room for drugs that target new targets while meeting the
particular needs of the pediatric population.
Questions Answered in This Report
- JIA is an umbrella term for seven distinct diagnoses. How are the various JIA subtypes defined?
How are they diagnosed? How does their treatment differ?
- The drugs used in the treatment of JIA are identical to those used in adult rheumatic diseases.
What are the first-line therapies for JIA? What factors drive prescribing decisions? How safe
and efficacious are these treatments in children?
- Not all JIA patients are sufficiently treated with available therapies. Which specific unmet needs
remain? What agents are in development for JIA? How will these agents fit into the treatment
patterns for these diseases? What do thought leaders say about emerging agents?
Scope
- Overview of JIA: Oligoarthritis; polyarthritis; enthesitis-related arthritis; psoriatic
arthritis; systemic JIA; diagnosis of JIA.
- Epidemiology: Ten-year forecast for United States, France, Germany, Italy, Spain, United
Kingdom, and Japan.
- Current therapies: nonsteroidal anti-infl ammatory drugs (NSAIDs); corticosteroids;
methotrexate; tumor necrosis factor-alpha (TNF-á) inhibitors; Orencia; Kineret; Rituxan.
- Emerging therapies: Rilonacept; canakinumab; tocilizumab.
- Opportunities in JIA: Qualitative market outlook for current and emerging agents; unmet
needs.
- Primary research: Thought-leader interviews from the United States, France, Germany,
and the United Kingdom.
|
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Overview of Juvenile Idiopathic Arthritis
- Subtypes of Juvenile Idiopathic Arthritis
- Oligoarthritis
- Polyarthritis
- Enthesitis-Related Arthritis
- Psoriatic Arthritis
- Systemic Juvenile Idiopathic Arthritis
- Diagnosis of Juvenile Idiopathic Arthritis
- Epidemiology
- Overview
- Disease Definition
- Methods
- Current Treatment Approaches
- Nonsteroidal Anti-Infl ammatory Drugs
- Corticosteroids
- Methotrexate
- Tumor Necrosis Factor-Alpha Inhibitors
- Kineret
- Orencia
- Rituxan
- Emerging Therapies for Juvenile Idiopathic Arthritis
- Regeneron’s Arcalyst
- Novartis’s Canakinumab
- Roche/Chugai’s Actemra
- Opportunities in the Treatment of Juvenile Idiopathic Arthritis
- Outlook for JIA Treatments
- Oligoarthritis
- Polyarthritis, Enthesitis-Related Arthritis, and Psoriatic Arthritis
- Systemic Juvenile Idiopathic Arthritis
- Ongoing Unmet Needs in Juvenile Idiopathic Arthritis
- Bibliography
- Tables
- 1. Juvenile Idiopathic Arthritis Disease Subtypes
- 2. Number of Diagnosed Prevalent Cases of Juvenile Idiopathic Arthritis in the Major Pharmaceutical Markets, 2008-2018
- 3. Classification Criteria for the Various Definitions of Juvenile Idiopathic Arthritis
- 4. Tumor Necrosis Factor-Alpha Inhibitors Used in the Treatment of Juvenile Idiopathic Arthritis
- 5. Emerging Agents in Juvenile Idiopathic Arthritis
- Figures
- 1. Treatment Algorithms for Subtypes of Juvenile Idiopathic Arthritis
|
Order Form * Please reference product number R55-649 when ordering or inquiring.
MindBranch, Inc.,
131 Ashland St., Suite 200 North Adams, MA 01247
tel: 800-774-4410
fax: +1-413-664-9791
www.mindbranch.com
|
